Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

C. Massard, J. Mateo, Y. Loriot, C. Pezaro, L. Albiges, N. Mehra, A. Varga, D. Bianchini, C. J. Ryan, D. P. Petrylak, G. Attard, L. Shen, K. Fizazi, J. de Bono

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Background: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and tolerability in patients with progressive mCRPC after docetaxel (phase I), and after docetaxel and abiraterone (phase II) (NCT01511536). Patients and methods: The primary objectives were to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cabazitaxel plus abiraterone (phase I), and the prostate-specific antigen (PSA) response defined as a≥50% decrease confirmed ≥3 weeks later with this combination (phase II). Results: Ten patients were enrolled in the phase I component; nine were evaluable. No DLTs were identified. The MTD was established as the approved doses for both drugs (cabazitaxel 25 mg/m2 every 3 weeks and abiraterone 1000mg once daily). Daily abiraterone treatment did not impact on cabazitaxel clearance. Twenty-seven patients received cabazitaxel plus abiraterone plus prednisone (5mg twice daily) in phase II. The median number of cycles administered (cabazitaxel) was seven (range: 1-28). Grade 3-4 treatment-emergent adverse events included asthenia (in 5 patients; 14%), neutropenia (in 5 patients; 14%) and diarrhea (in 3 patients; 8%). Nine patients (24%) required dose reductions of cabazitaxel. Of 26 evaluable patients, 12 achieved a PSA response [46%; 95% confidence interval (CI): 26.6-66.6%]. Median PSA-progression-free survival was 6.9 months (95% CI: 4.1-10.3 months). Of 14 patients with measurable disease at baseline, 3 (21%) achieved a partial response per response evaluation criteria in solid tumors. Conclusions: The combination of cabazitaxel and abiraterone has a manageable safety profile and shows antitumor activity in patients previously treated with docetaxel and abiraterone.

Original languageEnglish (US)
Pages (from-to)90-95
Number of pages6
JournalAnnals of Oncology
Issue number1
StatePublished - Jan 1 2017

Bibliographical note

Funding Information:
The authors would like to thank participating patients and their families. This study was sponsored by Sanofi Genzyme; editorial and production support was provided by Olga Ucar and Danielle Lindley of MediTech Media, funded by Sanofi Genzyme. The authors were fully responsible for all content and editorial decisions, were involved in all stages of manuscript preparation and have approved the final version. We acknowledge support to The Institute of Cancer Research/Royal Marsden Drug Development Unit through an Experimental Cancer Medical Centre (ECMC) grant from Cancer Research UK and the Department of Health (Ref: C51/A7401) and NHS funding to the NIHR Biomedical Research Centre to the Royal Marsden.

Publisher Copyright:
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.


  • Abiraterone
  • Cabazitaxel
  • Combination
  • Prostate cancer


Dive into the research topics of 'Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone'. Together they form a unique fingerprint.

Cite this